Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease
Open Access
- 31 December 2019
- journal article
- Published by Kurume Medical Journal in The Kurume Medical Journal
- Vol. 66 (4) , 209-215
Abstract
Summary: Background: Fecal calprotectin has been proposed as a useful biomarker of disease activity in inflammatory bowel disease (IBD). However, the role of calprotectin in systemic circulation is not well established. Thus, this study aimed to quantify serum calprotectin levels to identify a potential inflammatory marker for IBD. Methods: Ninety-eight patients with ulcerative colitis (UC) and 105 patients with Crohn’s disease (CD) were prospectively enrolled and clinically scored. Ninety-two healthy, age-matched subjects served as controls. Blood samples from UC and CD patients and controls were analyzed for serum calprotectin levels and routine laboratory parameters. Disease activity was assessed by partial Mayo score and Harvey-Bradshaw index for UC and CD, respectively. Results: Serum calprotectin levels were higher in CD and UC patients than in controls and were higher during active disease than during inactive disease in CD but not in UC. In UC, serum calprotectin levels were correlated with C-reactive protein (CRP) but not with other laboratory parameters or disease activity. In CD, serum calprotectin levels were positively correlated with disease activity, serum CRP, and platelet count. In UC and CD, serum calprotectin and CRP levels increased during the acute phase and decreased towards remission. Conclusions: Serum calprotectin is an inflammatory marker in IBD but might be more effective in evaluating patients with CD than those with UC. Further studies are needed to confirm these findings and to better determine the specific uses of serum calprotectin in routine practice.Keywords
This publication has 25 references indexed in Scilit:
- Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritisKidney International, 2013
- Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritisArthritis Research & Therapy, 2011
- Phagocyte-specific S100A8/A9 Protein Levels During Disease Exacerbations and Infections in Systemic Lupus ErythematosusThe Journal of Rheumatology, 2009
- The fundamental basis of inflammatory bowel diseaseJournal of Clinical Investigation, 2007
- Expression of Myeloid-Related Protein-8 and -14 in Patients With Acute Kawasaki DiseaseJACC, 2006
- Differential expression and response to anti‐TNFα treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritisThe Journal of Pathology, 2005
- Effect of Porphyromonas gingivalis Lipopolysaccharide, Tumor Necrosis Factor‐α, and Interleukin‐1β on calprotectin release in human monocytesJournal of Periodontology, 2003
- Calprotectin release from human neutrophils is induced by Porphyromonas gingivalis lipopolysaccharide via the CD‐14–Toll‐like receptor–nuclear factor κB pathwayJournal of Periodontal Research, 2003
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987
- A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITYThe Lancet, 1980